Recommendations on the use of everolimus in lung transplantation

Transplantation Reviews

Volumn 27, Issue 1, 2013, Pages 9-16

  De Pablo, A ^a   Santos, F ^b   Sole A ^c   Borro, J M ^d   Cifrian, J M ^e   Laporta, R ^f   Monforte, V ^g   Roman A ^g   la Torre, M de ^d   Ussetti, P ^f   Zurbano, F ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g Universitari Vall d'Hebron   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; ERYTHROMYCIN; EVEROLIMUS; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE PROTEIN; PHENOBARBITAL; PHENYTOIN; PYRROLE DERIVATIVE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ANEMIA; ANGIONEUROTIC EDEMA; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; B LYMPHOCYTE; BACTERIAL PNEUMONIA; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; EDEMA; EPISTAXIS; FIBROBLAST; GRAFT RECIPIENT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOPENIA; LUNG TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MESENCHYME CELL; MOUTH ULCER; MYCOSIS; NAUSEA; PERICARDIAL EFFUSION; PLEURA EFFUSION; PROTEINURIA; REVIEW; RHINOPHARYNGITIS; STEADY STATE; T LYMPHOCYTE; TACHYCARDIA; THROMBOCYTOPENIA;

EID: 84873566763     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2012.11.001     Document Type: Review

References (89)

1. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244.
2. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562.
3. Dantal J., Berthoux F., Moal M.C., et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010, 23:1084.
4. Vigano M., Tuzcu M., Benza R., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007, 26:584.
5. Lehmkuhl H.B., Arizon J., Vigano M., et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009, 88:115.
6. Salminen U.S., Alho H., Taskinen E., et al. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model. Transplant Proc 1998, 30:2204.
7. Doyle R.L., Hertz M.I., Dunitz J.M., et al. RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. J Heart Lung Transplant 2001, 20:330.
8. Groetzner J., Wittwer T., Kaczmarek I., et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006, 81:355.
9. Lischke R., Simonek J., Matousovic K., et al. Initial single-center experience with sirolimus after lung transplantation. Transplant Proc 2006, 38:3006.
10. Parada M.T., Alba A., Sepulveda C. Everolimus in lung transplantation in Chile. Transplant Proc 2010, 42:328.
11. Snell G.I., Levvey B.J., Zheng L., et al. Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation. Am J Transplant 2005, 5:1446.
12. Snell G.I., Valentine V.G., Vitulo P., et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006, 6:169.
13. Glanville A., Aboyoun C., Klepetko W., et al. One-year results of the first 120 patients enrolled in a 3-year randomised open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung, and single lung transplant recipients. J Heart Lung Transplant 2009, 28:S302. (Abstract 682).
14. Glanville A., Aboyoun C., Klepetko W., et al. One-year results of the CeMyLungs Study, a 3-year randomized, open label, multi-centre investigator driven sudy comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporine (using C2 monitoring) and corticosteroids for the prevention of the bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplant recipients. J Heart Lung Transplant 2009, 29:S94. (Abstract 278).
15. Gullestad L., Mortensen S.A., Eiskjaer H., et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010, 90:1581.
16. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002, 11:1845.
17. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36.
18. Azzola A., Havryk A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77:275.
19. Chapman T.M., Perry C.M. Everolimus. Drugs 2004, 64:861.
20. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004, 43:83.
21. Kovarik J.M., Kaplan B., Silva H.T., et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6months after kidney transplantation. Am J Transplant 2003, 3:606.
22. Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001, 69:48.
23. Kovarik J.M., Eisen H., Dorent R., et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 2003, 22:1117.
24. Kovarik J.M., Snell G.I., Valentine V., et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006, 25:440.
25. Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002, 36:981.
26. Kovarik J.M., Hsu C.H., McMahon L., et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001, 70:247.
27. Starling R.C., Hare J.M., Hauptman P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004, 4:2126.
28. Taylor A.L., Watson C.J., Bradley J.A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005, 56:23.
29. Valente J.F., Hricik D., Weigel K., et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003, 3:1128.
30. Troppmann C., Pierce J.L., Gandhi M.M., et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003, 76:426.
31. Flechner S.M., Zhou L., Derweesh I., et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003, 76:1729.
32. Trotter J.F., Wachs M., Bak T., et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001, 7:343.
33. Kuppahally S., Al-Khaldi A., Weisshaar D., et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006, 6:986.
34. Fishbein T.M., Florman S., Gondolesi G., et al. Intestinal transplantation before and after the introduction of sirolimus. Transplantation 2002, 73:1538.
35. King-Biggs M.B., Dunitz J.M., Park S.J., et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003, 75:1437.
36. Groetzner J., Kur F., Spelsberg F., et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004, 23:632.
37. van der Vliet J.A., Willems M.C., de Man B.M., et al. Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006, 82:1477.
38. Willems M.C., van der Vliet J.A., de Man B.M., et al. Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010, 18:98.
39. Dutly A.E., Gaspert A., Inci I., et al. The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg 2003, 24:154.
40. Albano L., Berthoux F., Moal M.C., et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009, 88:69.
41. Bouzas-Mosquera A., Crespo-Leiro M.G., Paniagua M.J., et al. Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation. Transplant Proc 2008, 40:3027.
42. Snell G.I., Levvey B.J., Chin W., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002, 21:540.
43. Roman A., Ussetti P., Zurbano F., et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011, 43:2693.
44. Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc 2004, 36:220S.
45. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1.
46. Christie J.D., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010, 29:1104.
47. Ojo A.O. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007, 27:498.
48. Barraclough K., Menahem S.A., Bailey M., et al. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant 2006, 25:1431.
49. Esposito C., De Mauri A., Vitulo P., et al. Risk factors for chronic renal dysfunction in lung transplant recipients. Transplantation 2007, 84:1701.
50. Flechner S.M., Kobashigawa J., Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008, 22:1.
51. Mulay A.V., Cockfield S., Stryker R., et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006, 82:1153.
52. Hunt J., Lerman M., Magee M.J., et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005, 24:1863.
53. Moro Lopez J.A., Almenar L., Martinez-Dolz L., et al. Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime. Transplantation 2009, 87:538.
54. Boffini M., Sansone F., Patane F., et al. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. Transplant Proc 2009, 41:1349.
55. Gude E., Gullestad L., Arora S., et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010, 29:641.
56. Gustafsson F., Ross H.J., Delgado M.S., et al. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007, 26:998.
57. Strueber M., Stefan F., Simon A., et al. Everolimus versus mycophenolate mofetil in de novo immunosuppression after lung transplantation-interims analysis of a prospective, randomized, clinical study. J Heart Lung Transplant 2008, 28:S205. (abstract 401).
58. Venuta F., De Giacomo T., Rendina E.A., et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004, 78:1940.
59. Stephany B.R., Boumitri M., Budev M., et al. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009, 28:564.
60. Cahill B.C., Somerville K.T., Crompton J.A., et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003, 22:169.
61. Villanueva J., Boukhamseen A., Bhorade S.M. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 2005, 24:421.
62. Hoda M., Jaksch P., Zweytick B., et al. Combination of everolimus with low-dose calcineurin-inhibitors in lung transplant recipients with chronic renal insufficiency. J Heart Lung Transplant 2008, 27:S76. (Abstract 45).
63. Gullestad L., Iversen M., Mortensen S.A., et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010, 89:864.
64. Arora S., Rundqvist B., Mortensen S.-A., et al. Everolimus introduction and calcineurine reduction in thoracic transplant recipients with advanced chronic renal failure. J Heart Lung Transplant 2011, 30:S25. (Abstract 53).
65. Sato M., Waddell T.K., Wagnetz U., et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011, 30:735.
66. Kim Y., Tedesco-Silva H., Johnston T., et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study. Transplantation 2010, 90:256. (Abstract 1615).
67. Tedesco Silva H., Cibrik D., Johnston T., et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401.
68. San Juan R., Aguado J.M., Lumbreras C., et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008, 47:875.
69. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000, 97:4285.
70. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847.
71. Vigano M., Dengler T., Mattei M.F., et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 2010, 12:23.
72. Hill J.A., Hummel M., Starling R.C., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84:1436.
73. Potena L., Bianchi I., D'Agostino C., et al. Everolimus treatment reduces the need for anti-CMV prophylaxis in de novo heart transplant recipients. J Heart Lung Transplant 2011, 30:S64. (Abstract 172).
74. Delgado J.F., Manito N., Almenar L., et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011, 13:136.
75. de la Torre-Cisneros J., Farinas M.C., Caston J.J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735.
76. Fernandez A., Marcen R., Pascual J., et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006, 38:2453.
77. Garcia V.D., Bonamigo Filho J.L., Neumann J., et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003, 16:202.
78. Pal S.K., Figlin R.A. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol 2011, 6:5.
79. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514.
80. Masetti M., Potena L., Pantaleo M.A., et al. Outcome of heart transplant recipients with cancer: focusing on the role of surgery, staging and immunosuppressive therapy. J Heart Lung Transplant 2011, 30:S47. (Abstract 120).
81. Campistol J.M., Gutierrez-Dalmau A., Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004, 77:760.
82. Campistol J.M., Albanell J., Arns W., et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007, 22(Suppl. 1):i36.
83. Manito N., Delgado J.F., Crespo-Leiro M.G., et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010, 24:129.
84. Sanchez-Fructuoso A.I., Ruiz J.C., Perez-Flores I., et al. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc 2010, 42:3050.
85. Zweytick B., Ghanim B., Sillipp J., et al. Side effects in a calcineurin inhibitors-everolimus based immunosuppressive regime in lung transplant recipients. J Heart Lung Transplant 2010, 29:S69. (Abstract 197).
86. Ussetti P., Carreno M., García-Gallo C., et al. mTOR inhibitors (mTOR-I) and proteinuria after lung transplantation. J Heart Lung Transplant 2008, 27:S75.
87. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182:396.
88. Exposito V., de Prada J.A., Gomez-Roman J.J., et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008, 27:797.
89. Fuchs U., Zittermann A., Berthold H.K., et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005, 79:981.